XIAP and melanoma: Although the presence of disseminated disease was not a contraindication of ILP for in-transit melanoma, the current treatment of these patients is undoubtedly immunotherapy and targeted therapies, as shown by the following therapeutic algorithm that we propose (Figure 4):